JP2011505800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505800A5 JP2011505800A5 JP2010536531A JP2010536531A JP2011505800A5 JP 2011505800 A5 JP2011505800 A5 JP 2011505800A5 JP 2010536531 A JP2010536531 A JP 2010536531A JP 2010536531 A JP2010536531 A JP 2010536531A JP 2011505800 A5 JP2011505800 A5 JP 2011505800A5
- Authority
- JP
- Japan
- Prior art keywords
- gpcr
- parent
- receptor
- mutant
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 105
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 105
- 239000003446 ligand Substances 0.000 claims 23
- 238000000034 method Methods 0.000 claims 21
- 102000005962 receptors Human genes 0.000 claims 19
- 108020003175 receptors Proteins 0.000 claims 19
- 125000000539 amino acid group Chemical group 0.000 claims 15
- 150000001413 amino acids Chemical class 0.000 claims 13
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 11
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 11
- 102000017922 Neurotensin receptor Human genes 0.000 claims 11
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 10
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 9
- 230000035772 mutation Effects 0.000 claims 9
- 102000009346 Adenosine receptors Human genes 0.000 claims 6
- 108050000203 Adenosine receptors Proteins 0.000 claims 6
- 108060003370 Neurotensin receptor Proteins 0.000 claims 6
- 101500028886 Rattus norvegicus Neurotensin Proteins 0.000 claims 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 5
- 229960005305 adenosine Drugs 0.000 claims 5
- GJLXVWOMRRWCIB-MERZOTPQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanamide Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=C(O)C=C1 GJLXVWOMRRWCIB-MERZOTPQSA-N 0.000 claims 4
- 102000018697 Membrane Proteins Human genes 0.000 claims 4
- 108010052285 Membrane Proteins Proteins 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 2
- 102000017910 Adrenergic receptor Human genes 0.000 claims 2
- 108091006027 G proteins Proteins 0.000 claims 2
- 102000030782 GTP binding Human genes 0.000 claims 2
- 108091000058 GTP-Binding Proteins 0.000 claims 2
- 239000000232 Lipid Bilayer Substances 0.000 claims 2
- 230000003196 chaotropic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 108010049777 Ankyrins Proteins 0.000 claims 1
- 102000008102 Ankyrins Human genes 0.000 claims 1
- 102000003916 Arrestin Human genes 0.000 claims 1
- 108090000328 Arrestin Proteins 0.000 claims 1
- 101001086405 Bos taurus Rhodopsin Proteins 0.000 claims 1
- 101100392772 Caenorhabditis elegans gln-2 gene Proteins 0.000 claims 1
- 102000008924 GPCR kinases Human genes 0.000 claims 1
- 108050000878 GPCR kinases Proteins 0.000 claims 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 claims 1
- 101000596394 Homo sapiens Vesicle-fusing ATPase Proteins 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102000008944 RGS Proteins Human genes 0.000 claims 1
- 108010074020 RGS Proteins Proteins 0.000 claims 1
- 102100035054 Vesicle-fusing ATPase Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000011948 assay development Methods 0.000 claims 1
- 108010007701 calcyon Proteins 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000007876 drug discovery Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000055647 human CSF2RB Human genes 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- -1 such as an antibody Proteins 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0724051.8A GB0724051D0 (en) | 2007-12-08 | 2007-12-08 | Mutant proteins and methods for producing them |
| PCT/GB2008/004032 WO2009071914A2 (en) | 2007-12-08 | 2008-12-08 | Mutant proteins and methods for producing them |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015032798A Division JP6567291B2 (ja) | 2007-12-08 | 2015-02-23 | 変異体タンパク質とその製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011505800A JP2011505800A (ja) | 2011-03-03 |
| JP2011505800A5 true JP2011505800A5 (enExample) | 2012-02-02 |
Family
ID=38983182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010536531A Pending JP2011505800A (ja) | 2007-12-08 | 2008-12-08 | 変異体タンパク質とその製造方法 |
| JP2015032798A Active JP6567291B2 (ja) | 2007-12-08 | 2015-02-23 | 変異体タンパク質とその製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015032798A Active JP6567291B2 (ja) | 2007-12-08 | 2015-02-23 | 変異体タンパク質とその製造方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8748182B2 (enExample) |
| EP (2) | EP2220229B1 (enExample) |
| JP (2) | JP2011505800A (enExample) |
| AU (1) | AU2008332896B2 (enExample) |
| CA (1) | CA2708037C (enExample) |
| DK (1) | DK2220229T3 (enExample) |
| ES (1) | ES2972473T3 (enExample) |
| GB (2) | GB0724051D0 (enExample) |
| PL (1) | PL2568045T3 (enExample) |
| WO (1) | WO2009071914A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101688203B (zh) | 2007-03-22 | 2013-12-11 | 赫普泰雅治疗有限公司 | 突变的g蛋白偶联受体及其选择方法 |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| GB0724860D0 (en) * | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
| GB0802474D0 (en) | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
| US20110112037A1 (en) * | 2008-03-05 | 2011-05-12 | Heptares Therapeutics Limited BioPark | Crystal structure |
| GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
| EP3333185A1 (en) * | 2010-08-20 | 2018-06-13 | Heptares Therapeutics Limited | Mutant gpcrs |
| US20140031525A1 (en) | 2011-01-21 | 2014-01-30 | Heptares Therapeutics Limited | Mutant g-protein coupled receptor proteins and methods for producing them |
| CA2827187C (en) | 2011-02-23 | 2019-01-08 | Massachusetts Institute Of Technology | Water soluble membrane proteins and methods for the preparation and use thereof |
| WO2012120315A2 (en) | 2011-03-10 | 2012-09-13 | Heptares Therapeutics Limited | Mutant proteins and methods for producing them |
| CN107739408A (zh) | 2011-08-10 | 2018-02-27 | 赫普泰雅治疗有限公司 | 稳定的蛋白质 |
| ES2676827T3 (es) | 2012-06-01 | 2018-07-25 | Heptares Therapeutics Limited | Ensayos |
| CU24181B1 (es) * | 2012-11-09 | 2016-04-25 | Ct De Inmunología Molecular | POLIPÉPTIDOS DERIVADOS DEL TGFß |
| CN105102478A (zh) | 2013-01-30 | 2015-11-25 | 弗拉芒区生物技术研究所 | 用于筛选和药物发现目的的新型嵌合多肽 |
| WO2014140586A2 (en) | 2013-03-15 | 2014-09-18 | Medical Research Council | Mutant proteins and methods for their production |
| US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
| WO2016070022A1 (en) | 2014-10-31 | 2016-05-06 | Abilita Bio, Inc. | Modified membrane spanning proteins and methods for the preparation and use thereof |
| EP3344043A4 (en) * | 2015-09-04 | 2019-07-10 | The Scripps Research Institute | METHOD FOR IDENTIFYING NEW ANTIBIOTICS AND RELATED COMPOSITIONS |
| GB201601690D0 (en) | 2016-01-29 | 2016-03-16 | Heptares Therapeutics Ltd | G proteins |
| SMT201900460T1 (it) | 2016-02-29 | 2019-09-09 | Ose Immunotherapeutics | Anticorpi non antagonisti diretti contro la catena alfa del dominio extracellulare del recettore di il17 e loro uso nel trattamento del cancro |
| US10845367B2 (en) | 2016-05-04 | 2020-11-24 | Abilita Bio, Inc. | Modified multispanning membrane polypeptides and methods of use thereof to screen therapeutic agents |
| WO2018150260A1 (en) * | 2017-02-16 | 2018-08-23 | Institut Pasteur | Method for the identification of mutated proteins having modified thermal stability |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6780613B1 (en) * | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| ATE189526T1 (de) | 1988-10-28 | 2000-02-15 | Genentech Inc | Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| JP3147916B2 (ja) * | 1991-03-08 | 2001-03-19 | 森永製菓株式会社 | 体外免疫方法 |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US20030036092A1 (en) * | 1991-11-15 | 2003-02-20 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
| US5585277A (en) * | 1993-06-21 | 1996-12-17 | Scriptgen Pharmaceuticals, Inc. | Screening method for identifying ligands for target proteins |
| JPH10500951A (ja) | 1994-05-23 | 1998-01-27 | スミスクライン・ビーチャム・コーポレイション | コードされた組合せライブラリー |
| US20020028443A1 (en) * | 1999-09-27 | 2002-03-07 | Jay M. Short | Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process |
| AU2020497A (en) | 1996-03-27 | 1997-10-17 | Susan R. George | Receptor and transporter antagonists |
| AU2728297A (en) * | 1996-04-15 | 1997-11-07 | Board Of Trustees Of The Leland Stanford Junior University | Soluble 7-transmembrane domain G-protein-coupled receptor compositions and me thods |
| US6153410A (en) * | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| US6555339B1 (en) | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
| CA2323638A1 (en) * | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| US7094593B1 (en) * | 1998-09-01 | 2006-08-22 | Basf Aktiengesellschaft | Method for improving the function of heterologous G protein-coupled receptors |
| IL149569A0 (en) | 1999-11-17 | 2002-11-10 | Arena Pharm Inc | Endogenous and non-endogenous versions of human g protein-coupled receptors |
| AU2001286945A1 (en) * | 2000-08-30 | 2002-03-13 | John Hopkins University School Of Medicine | Identification of activated receptors and ion channels |
| US6448377B1 (en) * | 2000-09-27 | 2002-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Modified G protein sunbunits |
| CA2425149A1 (en) * | 2000-10-26 | 2002-08-01 | New England Medical Center Hospitals, Inc. | Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents |
| CN1516706A (zh) | 2001-02-26 | 2004-07-28 | 阿伦纳药品公司 | 人g蛋白偶联受体的内源性和非内源性形式 |
| US7208279B2 (en) * | 2001-03-14 | 2007-04-24 | Caden Biosciences, Inc. | Method for identifying inhibitors of G protein coupled receptor signaling |
| JPWO2002079784A1 (ja) * | 2001-03-30 | 2004-07-22 | サントリー株式会社 | Ｇ蛋白質結合型レセプターの構造モデルおよび当該構造モデルを用いたｇ蛋白質結合型レセプターに結合するリガンドの設計方法 |
| US20030129649A1 (en) * | 2001-04-24 | 2003-07-10 | Kobilka Brian K. | Conformational assays to detect binding to G protein-coupled receptors |
| EP1438337B1 (en) | 2001-10-25 | 2006-09-20 | Astex Therapeutics Limited | Crystals of cytochrome p450 2c9, structures thereof and their use |
| US7115377B2 (en) * | 2001-10-26 | 2006-10-03 | Atto Bioscience, Inc. | Cell-based assays for G-protein-coupled receptor-mediated activities |
| EP1505074A4 (en) | 2002-04-24 | 2005-12-21 | Banyu Pharma Co Ltd | CONSTITUTATIVE ACTIVE MUTANTS OF A HISTAMINE H3 RECEPTOR AND ITS USES |
| ATE457728T1 (de) * | 2002-05-01 | 2010-03-15 | Vertex Pharma | Kristallstruktur des aurora-2 proteins und dessen bindungstaschen |
| US7745161B2 (en) * | 2003-12-19 | 2010-06-29 | Palo Alto Research Center Incorporated | Amplification of enzymatic reactions for use with an enthalpy array |
| US20050287121A1 (en) * | 2004-05-12 | 2005-12-29 | Merchiers Pascal G | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| WO2005121755A1 (en) | 2004-06-14 | 2005-12-22 | Commonwealth Scientific And Industrial Research Organisation | Cell free g-protein coupled receptor and ligand assay |
| US20060188964A1 (en) | 2004-07-28 | 2006-08-24 | Filippo Mancia | Processing for producing and crystallizing G-protein coupled receptors |
| US20070154947A1 (en) * | 2005-08-31 | 2007-07-05 | The Trustees Of Princeton University | Chemical biodiscriminator |
| WO2007097820A2 (en) * | 2005-11-18 | 2007-08-30 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
| CN101688203B (zh) * | 2007-03-22 | 2013-12-11 | 赫普泰雅治疗有限公司 | 突变的g蛋白偶联受体及其选择方法 |
| GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| GB0724860D0 (en) * | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
| GB0802474D0 (en) | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
| US20110112037A1 (en) * | 2008-03-05 | 2011-05-12 | Heptares Therapeutics Limited BioPark | Crystal structure |
| CN102046684B (zh) * | 2008-05-30 | 2013-01-16 | 旭硝子株式会社 | 硬质发泡合成树脂及其制造方法 |
| GB0910725D0 (en) * | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
| EP3333185A1 (en) * | 2010-08-20 | 2018-06-13 | Heptares Therapeutics Limited | Mutant gpcrs |
-
2007
- 2007-12-08 GB GBGB0724051.8A patent/GB0724051D0/en not_active Ceased
-
2008
- 2008-12-08 WO PCT/GB2008/004032 patent/WO2009071914A2/en not_active Ceased
- 2008-12-08 CA CA2708037A patent/CA2708037C/en active Active
- 2008-12-08 ES ES12196192T patent/ES2972473T3/es active Active
- 2008-12-08 EP EP08856833.2A patent/EP2220229B1/en active Active
- 2008-12-08 JP JP2010536531A patent/JP2011505800A/ja active Pending
- 2008-12-08 EP EP12196192.4A patent/EP2568045B1/en active Active
- 2008-12-08 PL PL12196192.4T patent/PL2568045T3/pl unknown
- 2008-12-08 DK DK08856833.2T patent/DK2220229T3/da active
- 2008-12-08 GB GB1000387.9A patent/GB2467830B/en active Active
- 2008-12-08 AU AU2008332896A patent/AU2008332896B2/en active Active
- 2008-12-08 US US12/746,674 patent/US8748182B2/en active Active
-
2015
- 2015-02-23 JP JP2015032798A patent/JP6567291B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011505800A5 (enExample) | ||
| Erlandson et al. | Structural basis for G protein–coupled receptor signaling | |
| Kenakin | Drug efficacy at G protein–coupled receptors | |
| Filipek et al. | The Crystallographic Model of Rhodopsin and Its Use in Studies of Other G Protein–Coupled Receptors | |
| EP3926045B1 (en) | Mutant proteins and methods for selecting them | |
| US8748182B2 (en) | Mutant proteins and methods for producing them | |
| Lefkowitz | Historical review: a brief history and personal retrospective of seven-transmembrane receptors | |
| Zhan et al. | Arrestin-3 binds the MAP kinase JNK3α2 via multiple sites on both domains | |
| Luo et al. | Lateral clustering of TLR3: dsRNA signaling units revealed by TLR3ecd: 3Fabs quaternary structure | |
| Frank et al. | Structure and function of glycosylated tandem repeats from Candida albicans Als adhesins | |
| JP7524234B2 (ja) | Ｇタンパク質 | |
| Kogut‐Günthel et al. | The path to the G protein‐coupled receptor structural landscape: Major milestones and future directions | |
| WO2009055509A2 (en) | Cholesterol consensus motif of membrane proteins | |
| Launay et al. | Modeling of mammalian olfactory receptors and docking of odorants | |
| Gui et al. | Understanding the regulation mechanisms of PAF receptor by agonists and antagonists: molecular modeling and molecular dynamics simulation studies | |
| Jongejan et al. | Delineation of Receptor‐Ligand Interactions at the Human Histamine H1 Receptor by a Combined Approach of Site‐Directed Mutagenesis and Computational Techniques–or–How to Bind the H1 Receptor | |
| Hoyne et al. | Properties of an insulin receptor with an IGF-1 receptor loop exchange in the cysteine-rich region | |
| Schlechtingen et al. | Structure− Activity Relationships of Dynorphin A Analogues Modified in the Address Sequence | |
| Carrillo et al. | Measurement of agonist-dependent and-independent signal initiation of α1b-adrenoceptor mutants by direct analysis of guanine nucleotide exchange on the G protein Gα11 | |
| Markl et al. | 10-Å cryoEM structure and molecular model of the myriapod (Scutigera) 6× 6mer hemocyanin: understanding a giant oxygen transport protein | |
| CN110869362A (zh) | A类gpcr结合性化合物改性体 | |
| JPWO2003091282A1 (ja) | ヒスタミン受容体ｈ３常活性変異体およびその利用 | |
| Dong et al. | Use of photoaffinity labeling to understand the molecular basis of ligand binding to the secretin receptor |